1
|
Elsharkawi M, Ghoneim B, Westby D, Jones D, Tawfick W, Walsh SR. Adipose-derived stem cells in patients with venous ulcers: Systematic review. Vascular 2023; 31:989-993. [PMID: 35491989 DOI: 10.1177/17085381221098279] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/11/2023]
Abstract
OBJECTIVES Few studies have reported on the safety and durability of adipose-derived stem cells (ADSCs) to support healing in patients with venous leg ulcers (VLU). To establish if there is any evidence to support ADSC use in VLU patients, a systematic review was conducted. METHODS A systematic review was conducted following the PRISMA guidelines. PubMed and Embase databases were searched for relevant papers. References from retrieved papers were reviewed to identify any extra eligible studies. RESULTS After duplicate removal, 950 papers were screened for eligibility of which 932 were excluded based on title and abstract. Four papers were included in the final analysis (one randomised study and three non-randomised studies). 66 patients in total received ADSCs for VLU treatment. The only randomised paper reported 6-month healing rates of 75% with ADSCs compared to 50% in controls. 100% healing was achieved in one study. The remaining 2 studies reported 25% and 58% healing; however, they included patients with relatively large VLUs. Pain scores decreased after ADSCs application where reported. No serious procedure related complications were reported. CONCLUSION ADSCs may enhance ulcer healing in patients with chronic VLU and appears safe based on initial reports. Large, randomised trials are needed to definitively establish the technique's role in VLU patients.
Collapse
Affiliation(s)
- Mohamed Elsharkawi
- Department of Vascular Surgery, University College Hospital Galway, Galway, Ireland
| | - Baker Ghoneim
- Department of Vascular Surgery, University College Hospital Galway, Galway, Ireland
- Department of Vascular Surgery, Cairo University Hospital, Cairo, Egypt
| | - Daniel Westby
- Department of Vascular Surgery, University College Hospital Galway, Galway, Ireland
| | - Deirdre Jones
- Department of Plastic Surgery, University College Hospital Galway, Galway, Ireland
| | - Wael Tawfick
- Department of Vascular Surgery, University College Hospital Galway, Galway, Ireland
| | - Stewart R Walsh
- Department of Vascular Surgery, University College Hospital Galway, Galway, Ireland
| |
Collapse
|
2
|
Martínez-deMiguel C, Segura-Bedmar I, Chacón-Solano E, Guerrero-Aspizua S. The RareDis corpus: A corpus annotated with rare diseases, their signs and symptoms. J Biomed Inform 2021; 125:103961. [PMID: 34879250 DOI: 10.1016/j.jbi.2021.103961] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 11/08/2021] [Accepted: 11/22/2021] [Indexed: 11/26/2022]
Abstract
Rare diseases affect a small number of people compared to the general population. However, more than 6,000 different rare diseases exist and, in total, they affect more than 300 million people worldwide. Rare diseases share as part of their main problem, the delay in diagnosis and the sparse information available for researchers, clinicians, and patients. Finding a diagnostic can be a very long and frustrating experience for patients and their families. The average diagnostic delay is between 6-8 years. Many of these diseases result in different manifestations among patients, which hampers even more their detection and the correct treatment choice. Therefore, there is an urgent need to increase the scientific and medical knowledge about rare diseases. Natural Language Processing (NLP) can help to extract relevant information about rare diseases to facilitate their diagnosis and treatments, but most NLP techniques require manually annotated corpora. Therefore, our goal is to create a gold standard corpus annotated with rare diseases and their clinical manifestations. It could be used to train and test NLP approaches and the information extracted through NLP could enrich the knowledge of rare diseases, and thereby, help to reduce the diagnostic delay and improve the treatment of rare diseases. The paper describes the selection of 1,041 texts to be included in the corpus, the annotation process and the annotation guidelines. The entities (disease, rare disease, symptom, sign and anaphor) and the relationships (produces, is a, is acron, is synon, increases risk of, anaphora) were annotated. The RareDis corpus contains more than 5,000 rare diseases and almost 6,000 clinical manifestations are annotated. Moreover, the Inter Annotator Agreement evaluation shows a relatively high agreement (F1-measure equal to 83.5% under exact match criteria for the entities and equal to 81.3% for the relations). Based on these results, this corpus is of high quality, supposing a significant step for the field since there is a scarcity of available corpus annotated with rare diseases. This could open the door to further NLP applications, which would facilitate the diagnosis and treatment of these rare diseases and, therefore, would improve dramatically the quality of life of these patients.
Collapse
Affiliation(s)
- Claudia Martínez-deMiguel
- Tissue Engineering and Regenerative Medicine group, Department of Bioengineering, Universidad Carlos III de Madrid, Avenidad de la Universidad, 30, Leganés 28911, Madrid, Spain
| | - Isabel Segura-Bedmar
- Human Language and Accesibility Technologies, Computer Science Department, Avenidad de la Universidad 30, Leganés 28911, Madrid, Spain.
| | - Esteban Chacón-Solano
- Tissue Engineering and Regenerative Medicine group, Department of Bioengineering, Universidad Carlos III de Madrid, Avenidad de la Universidad, 30, Leganés 28911, Madrid, Spain; Hospital Fundación Jiménez Díaz e, Instituto de Investigación, FJD, Av. de los Reyes Católicos 2, Madrid 28040, Madrid, Spain; Epithelial Biomedicine Division, CIEMAT, Madrid 28040, Madrid, Spain
| | - Sara Guerrero-Aspizua
- Tissue Engineering and Regenerative Medicine group, Department of Bioengineering, Universidad Carlos III de Madrid, Avenidad de la Universidad, 30, Leganés 28911, Madrid, Spain; Hospital Fundación Jiménez Díaz e, Instituto de Investigación, FJD, Av. de los Reyes Católicos 2, Madrid 28040, Madrid, Spain; Epithelial Biomedicine Division, CIEMAT, Madrid 28040, Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), C/Monforte de Lemos 3-5, Madrid 28029, Madrid, Spain
| |
Collapse
|